WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000; IF 1:50-200
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
Phospho-GRK 1 (S21) Polyclonal Antibody detects endogenous levels of GRK 1 protein only when phosphorylated at S21.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):RGsFD
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
63kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from human GRK1 around the phosphorylation site of Ser21. AA range:6-55
show all
Specificity:
Phospho-GRK 1 (S21) Polyclonal Antibody detects endogenous levels of GRK 1 protein only when phosphorylated at S21.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):RGsFD
This gene encodes a member of the guanine nucleotide-binding protein (G protein)-coupled receptor kinase subfamily of the Ser/Thr protein kinase family. The protein phosphorylates rhodopsin and initiates its deactivation. Defects in GRK1 are known to cause Oguchi disease 2 (also known as stationary night blindness Oguchi type-2). [provided by RefSeq, Jul 2008],
show all
Function:
Catalytic activity:ATP + [rhodopsin] = ADP + [rhodopsin] phosphate.,Disease:Defects in GRK1 are a cause of congenital stationary night blindness Oguchi type (CSNBO) [MIM:258100]; also known as Oguchi disease. Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision. CSNBO is an autosomal recessive form associated with fundus discoloration and abnormally slow dark adaptation.,Function:Phosphorylates rhodopsin thereby initiating its deactivation.,online information:Retina International's Scientific Newsletter,PTM:Autophosphorylated.,PTM:Farnesylation is required for full activity.,similarity:Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. GPRK subfamily.,similarity:Contains 1 AGC-kinase C-terminal domain.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 RGS domain.,tissue specificity:Retina and pineal gland.,
show all
Cellular Localization:
Membrane ; Lipid-anchor . Cell projection, cilium, photoreceptor outer segment . Subcellular location is not affected by light or dark conditions. .